|
| | |
|
Am J Psychiatry 1991; 148:1558-1561
Copyright © 1991 by American Psychiatric Association
Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy
E Hriso, T Kuhn, JC Masdeu and M Grundman
Department of Neurology, St. Vincent's Medical Center, New York, NY 10011.
OBJECTIVE: The authors attempted to determine whether patients with AIDS
are more susceptible to neuroleptic side effects than other patients.
METHOD: Retrospective chart review was used to assess the frequency and
severity of extrapyramidal symptoms in patients with AIDS and psychotic
patients without AIDS who had taken dopamine-blocking agents. The charts of
804 men younger than 50 years were reviewed, and patients were excluded if
they had not taken dopamine blockers, had taken them for more than 1 month,
had received concomitant antiparkinsonian agents, had focal brain lesions
or histories of Parkinson's disease or meningitis, had used cocaine,
amphetamines, or opiates within 1 month of admission, or, among the
comparison group, had HIV risk factors. For the remaining 31 AIDS and 32
comparison patients, age, duration of dopamine blocker treatment, dose in
chlorpromazine equivalents, and nature and severity of parkinsonian
complications were recorded. RESULTS: The mean drug dose and body weight
were significantly lower in the AIDS group. The likelihood of developing
extrapyramidal symptoms was 2.4 times as high among the AIDS patients as
among the comparison group. Such symptoms were developed by 50% of the AIDS
patients who received less than 4 mg/kg of chlorpromazine equivalents per
day and 78% of those who received more than 4 mg/kg per day. CONCLUSIONS:
These preliminary results suggest that AIDS patients are more susceptible
to extrapyramidal symptoms than psychotic patients without AIDS and that
neuroleptics should be used cautiously and in lower doses for patients with
AIDS.
This article has been cited by other articles:
|
|
|
|
 
M. J. Repetto and J. M. Petitto
Psychopharmacology in HIV-Infected Patients
Psychosom Med,
June 1, 2008;
70(5):
585 - 592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Claxton, J. J. Chen, and D. M. Swope
Drug-Induced Movement Disorders
Journal of Pharmacy Practice,
December 1, 2007;
20(6):
415 - 429.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Breitbart, R. Marotta, M. M. Platt, H. Weisman, M. Derevenco, C. Grau, K. Corbera, S. Raymond, S. Lund, and P. Jacobsen
A Double-Blind Trial of Haloperidol, Chlorpromazine, and Lorazepam in the Treatment of Delirium in Hospitalized AIDS Patients
Focus,
April 1, 2005;
3(2):
333 - 340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-J. Wang, L. Chang, N. D. Volkow, F. Telang, J. Logan, T. Ernst, and J. S. Fowler
Decreased brain dopaminergic transporters in HIV-associated dementia patients
Brain,
November 1, 2004;
127(11):
2452 - 2458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. I. Lee, J. Klesmer, and B. E. Hirsch
Neuroleptic Malignant Syndrome Associated With Use of Risperidone, Ritonavir, and Indinavir: A Case Report
Psychosomatics,
October 1, 2000;
41(5):
453 - 454.
[Full Text]
|
|
|
|
|
|
|
G. Zauli, P. Secchiero, L. Rodella, D. Gibellini, P. Mirandola, M. Mazzoni, D. Milani, D. R. Dowd, S. Capitani, and M. Vitale
HIV-1 Tat-mediated Inhibition of the Tyrosine Hydroxylase Gene Expression in Dopaminergic Neuronal Cells
J. Biol. Chem.,
February 11, 2000;
275(6):
4159 - 4165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Di Rocco, R. Roesler, J. Quevedo, R. Walz, M. Bianchin, and N. Sacktor
A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment
Neurology,
June 1, 1999;
52(9):
1920 - 1920.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1991
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
